title: [Allergic rhinitis update and its impact on asthma (ARIA 2008). Latin American perspective].
abstract: Rhinitis is the most frequent respiratory disease in most countries of the world. It is estimated that 600 million people suffer this condition. Allergic rhinitis is a public health problem at global level. Patients who suffer allergic rhinitis have from mild to annoying nasal symptoms which affect quality of life, cause sleep disorders, scholar and workplace absenteeism, and health expenditure. Rhinitis is frequently associated to co-morbidities such as sinusitis, otitis media, and especially asthma. Rhinitis is under-diagnosed and under-treated worldwide and also in Latin American countries. ARIA is the very first evidence-based guideline for the diagnosis and treatment of rhinitis with focus in its co-morbidities (2001), especially asthma published in 2001. In 2008 an update was published. ARIA recommends an integrative approach for management; including anti-histamines (second generation), intra-nasal corticosteroids, anti-leukotrienes and immunotherapy. It also provides a questionnaire to evaluate asthma and its severity in those patients suffering rhinitis. The prevalence of allergic rhinitis is quite high in Latin American countries and in recent years a great insight on the burden of this condition has been gained.
authors.affiliation: Facultad de Medicina, Universidad Católica de Córdoba, Argentina. cebaenac@arnet.com.ar
authors.forename: Carlos E Baena
authors.initials: CE
authors.lastname: Cagnani
authors.forename: Dirceu
authors.initials: D
authors.lastname: Solé
authors.forename: Sandra N González
authors.initials: SN
authors.lastname: Díaz
authors.forename: Mario E
authors.initials: ME
authors.lastname: Zernotti
authors.forename: Juan C
authors.initials: JC
authors.lastname: Sisul
authors.forename: Mario Sánchez
authors.initials: MS
authors.lastname: Borges
authors.forename: María Antonieta
authors.initials: MA
authors.lastname: Guzmán
authors.forename: Juan C
authors.initials: JC
authors.lastname: Ivancevich
authors.forename: Alfonso
authors.initials: A
authors.lastname: Cepeda
authors.forename: Noel Rodríguez
authors.initials: NR
authors.lastname: Pérez
authors.forename: José
authors.initials: J
authors.lastname: Gereda
authors.forename: Alvaro
authors.initials: A
authors.lastname: Cruz
authors.forename: Victor H
authors.initials: VH
authors.lastname: Croce
authors.forename: Nikolai
authors.initials: N
authors.lastname: Khaltaev
authors.forename: Jean
authors.initials: J
authors.lastname: Bousquet
mesh_terms: D000465:Algorithms; D018926:Anti-Allergic Agents / Q000600:supply & distribution / Q000627:therapeutic use; D001249:Asthma / Q000175:diagnosis / Q000453:epidemiology* / Q000628:therapy; D015897:Comorbidity; D003906:Developing Countries; D019317:Evidence-Based Medicine; D006801:Humans; D007843:Latin America / Q000453:epidemiology; D017410:Practice Guidelines as Topic; D015995:Prevalence; D012221:Rhinitis, Allergic, Perennial / Q000175:diagnosis / Q000453:epidemiology* / Q000628:therapy; D006255:Rhinitis, Allergic, Seasonal / Q000175:diagnosis / Q000453:epidemiology* / Q000628:therapy; D012959:Socioeconomic Factors; D014944:World Health Organization / Q000458:organization & administration
chemical_list: D018926:Anti-Allergic Agents